FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 301:577-579 September 13, 1979 Number 11 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

Since platelet cyclo-oxygenase is much more sensitive to inactivation by aspirin than is the enzyme in the arterial wall and low doses of aspirin may prevent thrombosis by blocking thromboxane synthesis, we conducted a randomized, double-blind trial of aspirin (160 mg per day) vs. placebo in 44 patients on chronic hemodialysis. The study was continued until there were 24 patients with thrombi and both groups had been under observation for a mean of nearly five months. Thrombi occurred in 18 of 25 (72 per cent) of patients given placebo and 16 of 19 (32 per cent) of those given aspirin (P less than 0.01). The incidence of thrombosis was reduced from 0.46 thrombi per patient month in the placebo group to 0.16 thrombi per patient month in the aspirin group (p less than 0.005). A dose of 160 mg of aspirin per day is an effective, nontoxic antithrombotic regimen in patients on hemodialysis.

This article has been cited by other articles:

• Patrono, C., Baigent, C., Hirsh, J., Roth, G. (2008). Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 199S-233S [Abstract] [Full Text]  
• Patrono, C., Rocca, B. (2008). Aspirin: Promise and Resistance in the New Millennium. Arterioscler. Thromb. Vasc. Bio. 28: s25-s32 [Abstract] [Full Text]  
• Holden, R. M., Harman, G. J., Wang, M., Holland, D., Day, A. G. (2008). Major Bleeding in Hemodialysis Patients. CJASN 3: 105-110 [Abstract] [Full Text]  
• Dixon, B. S, Beck, G. J, Dember, L. M, Depner, T. A, Gassman, J. J, Greene, T., Himmelfar, J., Hunsicker, L. G, Kaufman, J. S, Lawson, J. H, Meyers, C. M, Middleton, J. P, Radeva, M., Schwab, S. J, Whiting, J. F, Feldman, H. I (2005). Design of the Dialysis Access Consortium (DAC) Aggrenox prevention of access stenosis trial. Clin Trials 2: 400-412 [Abstract]  
• Patrono, C., Coller, B., FitzGerald, G. A., Hirsh, J., Roth, G. (2004). Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 234S-264S [Abstract] [Full Text]  
• Kaufman, J. S., O'Connor, T. Z., Zhang, J. H., Cronin, R. E., Fiore, L. D., Ganz, M. B., Goldfarb, D. S., Peduzzi, P. N. (2003). Randomized Controlled Trial of Clopidogrel plus Aspirin to Prevent Hemodialysis Access Graft Thrombosis. J. Am. Soc. Nephrol. 14: 2313-2321 [Abstract] [Full Text]  
• Vanholder, R. (2001). Vascular access: care and monitoring of function. Nephrol Dial Transplant 16: 1542-1545 [Full Text]  
• Patrono, C., Coller, B., Dalen, J. E., FitzGerald, G. A., Fuster, V., Gent, M., Hirsh, J., Roth, G. (2001). Platelet-Active Drugs : The Relationships Among Dose, Effectiveness, and Side Effects. Chest 119: 39S-63S [Full Text]  
• Szycher, M. (1999). End-Stage Renal Disease (ESRD) and Vascular Access Grafting: A Critical Review. J Biomater Appl 13: 297-350 [Abstract]  
• Patrono, C. (1994). Aspirin as an Antiplatelet Drug. NEJM 330: 1287-1294 [Full Text]  
• (1994). Collaborative overview of randomised trials of antiplatelet therapy - II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 308: 159-168 [Abstract] [Full Text]